Our Pipeline

Leadership Through Innovation


Crafting the treatments of tomorrow for today's orphan diseases.

Even with the aid of numerous databases, petabytes of medical and chemical data, advancements in artificial intelligence, and countless intelligent algorithms, AI drug discovery is a challenging endeavor. At Delta4 we pride ourselves in having implemented a sophisticated drug development process that combines the best of AI with the brilliant minds on our team. Our methodology and process are the results of years of experience and careful planning. They have already succeeded in taking compounds through the stages of drug discovery up to clinical trials while yielding promising patents along the way.

See What We're Working On

Innovative treatments for complex diseases

At Delta4, we aim to enhance and transform treatment across a broad range of complex as well as rare diseases by discovering and developing proprietary repositioned/repurposed drug candidates.

Delta4 Developments



In-silico Ongoing

In-vitro/ In-vivo

Clinical Planning

Phase IIa


Focal Segmental Glomerulosclerosis (FSGS)
Long COVID Anosmia
Acute COVID-19
Eosinophilic Esophagitis (EoE)
Autosomaldominant Polycystic Kidney Disease (ADPKD)
Long-COVID-19 Chronic Fatigue Syndrome (CFS)
Oligoarticular Juvenile Idiopathic Arthritis




In-silico Ongoing

In-vitro/ In-vivo

Clinical Planning

Phase IIa


Primary Biliary Cholangitis (PBC)


Our Drug Discovery and Development Process

Combining advanced algorithms and AI with the best of human ingenuity to create uncommon results.

The process begins with our revolutionary artificial intelligence-powered platform, Hyper-C. Our robust in-silico platform is the result of a combined 70 man-years of development and leverages 15+ major data stores and databases. Hyper-C harvests and analyzes data in order to discover undetected relationships between drugs and diseases on a compound level. It does this with unparalleled efficiency and speed, providing a precise shortlist of potential matches with a high probability of success.

Learn More About Hyper-C

Once Hyper-C’s library of thousands of proprietary algorithms and artificial intelligence has conducted the bulk of the analysis, reviewing volumes of data and iterating through models – accomplishing what may be impossible for human researchers to perform – it’s time for our exceptional team to get to work.

Where many AI drug discovery platforms operate like a black box making it difficult to explain results, Hyper-C delivers a clear mechanism of action hypothesis and biomarkers for patient stratification in clinical trials, making it easier for our team to interpret and work with the results, make decisions, and satisfy regulatory requirements.

Our team of molecular and computational biologists scrutinize the shortlist of compounds and meticulously examine the data in order to identify and move forward with the option that secures the highest probability of success.

A key step in the process is to secure the new intellectual property. Our team provides the basis and the background for the patent to be filed and can assist with additional steps to ensure that the intellectual property is protected.

After an exacting in-silico selection process followed by a rigorous examination from our team, the drug candidate is ready for the biological testing phase.

With much excitement, our team begins the testing process offering both the in-vitro and the animal models. We also have access to independent experts across various specialties that can assist with the process or verify results.

Finally, it’s time for the first phase of clinical testing. A unique advantage of Delta4 is that we have direct access to opinion leaders and study patients at medical universities in Austria and neighboring countries.

Our team can assist with future phases of clinical trials as well as drug approvals with regulatory agencies.

We’re always looking for new partners that help us strengthen our process and its capabilities.

Our Partners & Clients

Proud Member of Scientist.com

Streamlining Transparency and Cooperation

Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.

Get Involved

Learn how you can contribute to the exciting work happening at Delta4


Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.


Contact us to find out more about how you can invest with us and be a part of pioneering the next successful treatment.

Medical Community

Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.